Evidence map›Paper›PMID 24584077›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014

A Hitchhiker's guide to the blood-brain barrier: in trans delivery of a therapeutic enzyme.

Mark S Sands

Abstract readComment
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.Molecular therapy : the journal of the American Society of Gene Therapy · 2019
    Article
  2. Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Article
  3. Review
  4. Article
  5. Recent advances in gene therapy for lysosomal storage disorders.The application of clinical genetics · 2015
    Review
  6. Engineered antibody therapies coming of age for aging brains.Molecular therapy : the journal of the American Society of Gene Therapy · 2014
    Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Mark S SandsDepartments of Internal Medicine and Genetics, Washington University School of Medicine, St. Louis, Missouri, USA. Electronic address: msands@dom.wustl.edu.

Funding

PATHOPHYSIOLOGY AND NOVEL THERAPIES FOR BATTEN'S DISEASER01NS043205 · NINDS · WASHINGTON UNIVERSITY · PI SANDS, MARK S · 2003 to 2016
$4.0M
NOVEL THERAPIES FOR GLOBOID-CELL LEUKODYSTROPHYR01NS084861 · NINDS · WASHINGTON UNIVERSITY · PI SANDS, MARK S · 2013 to 2014
$806k
NINDS NIH HHS R01 NS043205NINDS NIH HHS R01 NS084861NINDS NIH HHS R01NS084861
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AminopeptidasesAnimalsApolipoproteins EBlood-Brain BarrierDipeptidyl-Peptidases and Tripeptidyl-PeptidasesHumansNeuronal Ceroid-LipofuscinosesPeptidesSerine ProteasesTripeptidyl-Peptidase 1AminopeptidasesApolipoproteins EDipeptidyl-Peptidases and Tripeptidyl-PeptidasesPeptidesSerine ProteasesTripeptidyl-Peptidase 1

Identifiers

PMID24584077
PMCPMC3944337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.